Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

NCI begins phase II trial of O6-benzylguanine/carmustine as glioma therapy

Feb. 23, 2000

Inhibitors of protein prenyltransferases remain a focus of R&D at Merck

Feb. 22, 2000

SBIR grant awarded to NeoRx for lymphoma radioimmunotherapy research

Feb. 22, 2000

Cantab reports anticancer potential for OX-40 ligand

Feb. 22, 2000

The Liposome Company meets with FDA to discuss Evacet NDA

Feb. 21, 2000

Pierre Fabre designs structurally novel inhibitors of protein prenylation

Feb. 18, 2000

New prostate cancer therapy to be studied in men with no other effective treatment options

Feb. 18, 2000

New series of taxanes designed at BMS

Feb. 18, 2000

Estrogenic activities described for 7alpha-thioestratrienes

Feb. 18, 2000

Purpurinimide photosensitizers with in vivo tumoricidal effects

Feb. 18, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...